(Q34033547)

English

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

1 reference

ChEBI release 2020-05-28

depressive disorder

1 reference

based on heuristic

inferred from title

author name string

Rakesh Jain

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Atul R Mahableshwarkar

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Paula L Jacobsen

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Yinzhong Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Michael E Thase

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

11 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

The International Journal of Neuropsychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

313-321

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Is it easier to find what you are looking for if you think you know what it looks like?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

Impact of major depression on chronic medical illness

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

Incidence and Duration of Side Effects and Those Rated as Bothersome With Selective Serotonin Reuptake Inhibitor Treatment for Depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

The STAR*D Project results: a comprehensive review of findings.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

The placebo effect: dissolving the expectancy versus conditioning debate.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

Innovative approaches for the development of antidepressant drugs: current and future strategies

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

Differentiating antidepressants of the future: efficacy and safety

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

21 January 2018

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychosocial Disability During the Long-term Course of Unipolar Major Depressive Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

7 January 2021

based on heuristic

inferred from DOI database lookup

Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

7 January 2021

based on heuristic

inferred from DOI database lookup

Antipsychotics in the treatment of delirium: a systematic review

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship between quality of interpersonal relationships and major depressive disorder: findings from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000727

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1017/S1461145712000727

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34033547&oldid=1968811886"